Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...

Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.

The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.

Johnson & Johnson said that its mid-stage study of icotrokinra, for the treatment of moderate to severe active ulcerative ...

JNJ's ulcerative colitis drug shows promise in mid-stage trials, with high response rates and well-tolerated safety profile ...

in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint of clinical response in all icotrokinra dose groups evaluated and demonstrated clinically ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

highlighted icotrokinra’s potential to change the treatment landscape for UC, citing its combination of efficacy, tolerability, and convenient once-daily oral dosing. Ulcerative colitis is a ...

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

H.C. Wainwright raised the firm’s price target on Protagonist Therapeutics (PTGX) to $80 from $54 and keeps a Buy rating on the shares. The ...